Mesalazine Suppresses Proinflammatory Cytokines in Patients with Acute Anterior Uveitis Independently of HLA-B27

References

• Kasper M, Walscheid K, Laffer B, et al. The phenotype of monocytes in anterior uveitis depends on the hla-B27 status. Front Immunol. 2018;9:1773–1882. doi:10.3389/fimmu.2018.01773.
   PubMed Web of Science ®Google Scholar
• Chang JH, Mc Cluskey JP, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364–388. doi:10.1016/j.survophthal.2005.04.003.
   PubMed Web of Science ®Google Scholar
• Linssen A, Rorhova A, Valkenburg HA, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci. 1991;32:2568–2578.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Leo PJ, Pointon JJ, et al. The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. Genes Immun. 2015;17:46–51. doi:10.1038/gene.2015.49.
   PubMed Web of Science ®Google Scholar
• Monnet D, Breban M, Hudry C, Dougados M, Pbrézin A. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: A study of 175 cases. Ophthalmology. 2002;111:802–809. doi:10.1016/j.ophtha.2003.07.011.
   Web of Science ®Google Scholar
• Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67:955–958. doi:10.1136/ard.2007.075754.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio EM, La Cava M, Tortorella P, Gharbyia M, Campanella M, Lannetti L (2016): Clinical features and complications of the HLA-B27-associated acute anterior uveitis: a metanalysis. Semin Ophtamology 32: 689–701.
   PubMed Web of Science ®Google Scholar
• Tuncer S, Adam YS, Urgancioglu M, Tugal-Tutkun I. Clinical features and outcomes of HLA-B27- positive and HLA-B27-negative acute anterior uveitis in a turkish patient population. Ocul Immunol Inflamm. 2005;13:367–373.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Practice Gastroenterol Hepatol. 2007;4:160–170. doi:10.1038/ncpgasthep0696.
   PubMedGoogle Scholar
• Bei Y, van Langeberg DR. Mesalazine preparations for the treatment of ulcerative colitis: are all created equal? World J Gastrointest Pharmacol Ther. 2015;6:137–144.
   PubMedGoogle Scholar
• Anthonisen RP, Wulf HR, Folkenborg O. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment: a double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol. 1973;7: 71-71.
   Google Scholar
• Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum. 1986;12:1427–1434. doi:10.1002/art.1780291202.
   Google Scholar
• Grisham MB. Role of reactive oxygen methabolites in inflammatory bowel disease. Curr Opin Gastroenterol. 1993;9:971–980. doi:10.1097/00001574-199309060-00013.
   Web of Science ®Google Scholar
• Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor Kappa B. J Clin Invest. 1998;101:1163–1174. doi:10.1172/JCI992.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;37:26448–26453. doi:10.1074/jbc.274.37.26448.
   Google Scholar
• Desremaux P, Hanauer SB. Understanding the mechanism of 5-ASA in treating colonic inflammation. Gastroenterol Hepatol (N Y). 2008;5:319–320.
   Google Scholar
• Hanauer S. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol The. 2004;4:60–65. doi:10.1111/j.1365-2036.2004.02048.x.
   Google Scholar
• Krasselt M, Bearwald C, Wagner U, Rossol M. CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther. 2013;15(5):R139. doi:10.1186/ar4321.
   PubMed Web of Science ®Google Scholar
• Carh G, Djursiiter R, Smedeghd G. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonucear leukocytes. Pharmacol Toxicol. 1989;65:121–127. doi:10.1111/j.1600-0773.1989.tb01141.x.
   PubMedGoogle Scholar
• Menu P, Mayor A, Zhou R, et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis. 2012;3:261–267. doi:10.1038/cddis.2011.132.
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140:821–832. doi:10.1016/j.cell.2010.01.040.
   PubMed Web of Science ®Google Scholar
• Bauernfeind F, Horvat G, Stutz A, et al. NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787–791.
   PubMed Web of Science ®Google Scholar
• Sanchez CL, Sims SG, Nowery JD, Mear GP. Endoplasmic reticulum stress differentially modulates the IL-6 family of cytokines in murine astrocytes and macrophages. Sci Rep. 2019;1:1–12.
   Google Scholar
• Kenna TJ, Lau MC, Keith P, et al. Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. Genes Immun. 2014;16:35–42. doi:10.1038/gene.2014.62.
   PubMed Web of Science ®Google Scholar
• Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol. 1984;3:407–412. doi:10.1016/0006-2952(84)90233-8.
   Google Scholar